Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Ogitani, Yusuke; Abe, Yuki; Iguchi, Takuma; Yamaguchi, Junko; Terauchi, Tomoko; Kitamura, Michiko; Goto, Kōichi; Goto, Motoaki; Oitate, Masataka; Yukinaga, Hideo; Yabe, Yoshiyuki; Nakada, Takashi; Masuda, Takeshi; Morita, Koji; Agatsuma, Toshinori

doi:10.1016/j.bmcl.2016.08.082

Cited by 36 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Researchers explored the antitumor ability of the antibody-drug conjugates (ADCs) that specifically destroyed B7-H3 positive expressing tumors, and found that established tumors and metastases were eradicated, and overall survival improved significantly, which demonstrate the anti-CD276-drug conjugates as promising reagents for highly selective broad-acting anti-cancer therapies [52]. A promising exatecan derivative (DX-8951 derivative, DXd), used for drug conjugation as DXd-ADC targeting B7-H3, showed effective antitumor efficacy as well as less adverse effects [53]. 131I-labeled anti-B7-H3 mAb (131I-4H7) had radiobiological and treatment effects on nude mice with human RCC.…”

Section: Targeting B7-h3 Therapymentioning

confidence: 95%

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy

2020

View full text Add to dashboard Cite

B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may be a promising target for cancer treatment. B7-H3 protein was demonstrated to be expressed in several kinds of tumor tissues including non-small-cell lung cancer (NSCLC) and prostate cancer. Its expression is highly associated with undesirable treatment outcomes and survival time, due to function of the immune checkpoint molecule. It was classified as either a co-stimulatory molecule for T cell activation or the nonimmunological role of regulating signaling pathways. Although there is still no agreed conclusion on the function of B7-H3, it may be a valuable target for cancer therapy. This review aims to provide a comprehensive, up-to-date summary of the advances in B7-H3 targeting approaches in cancer therapy. Although several challenges remain, B7-H3 offers a new therapeutic target with increased efficacy and less toxicity in future cancer treatment.

show abstract

Section: Targeting B7-h3 Therapymentioning

confidence: 95%

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy

2020

View full text Add to dashboard Cite

show abstract

“…Trastuzumab is conjugated to the antibody via a tetrapeptide linker, Gly-Gly-Phe-Gly ( Figure 10), which is cleavable by lysozymes [69]. The linker is connected to a Cys residue of the mAb through a maleimidocarpoyl component [66] and to a self-immolative amino methylene (AM) spacer [70].…”

Section: Gly-gly-phe-glymentioning

confidence: 99%

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

et al. 2020

View full text Add to dashboard Cite

2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

show abstract

“…There are six HER2-based ADCs in clinical trials aimed to improve the activity and maintain or enhance the T-DM1 immunity. Moreover, the utilization of the following cytotoxic drugs with different actions has been assessed: DS-8201a for the transmission of exatecan, a topoisomerase inhibitor [113][114][115][116] , and SYD985 [117,118] , a DNA-alkylating drug [119,120] , as well as ADCT-502 for the transmission of pyrrolobenzodiazepine that enters DNA minor grooves [121] .…”

Section: Adoptive Immunotherapy With Mabs and Adcsmentioning

confidence: 99%

“…This ADC shows a cell-related HER2 toxicity effect in laboratory conditions in pancreatic, breast, and gastric cancer cells. Human model studies have also indicated HER2specific activity in tumors with heterogeneous expression of HER2 [114,115] . This ADC has entered in phase 1 of clinical trial.…”

Section: Ds8201-amentioning

confidence: 99%

Immunotherapy for Breast Cancer Treatment

Simonian

Ghaffari

Negahdari

2021

ibj

View full text Add to dashboard Cite

Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel strategy in cancer treatment, has a potential in treating breast cancer patients. Although breast cancer has long been considered problematic to treat with immunotherapy, as it is immunologically "cold," numerous newer preclinical and clinical reports now recommend that immunotherapy has the capability to treat breast cancer patients. In this review, we highlight the different immunotherapy strategies in breast cancer treatment.

show abstract

Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Cited by 36 publications

References 31 publications

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

Immunotherapy for Breast Cancer Treatment

Contact Info

Product

Resources

About